UK Pompe disease is a small, well-characterised population run through a single academic-clinical consortium — and roughly a quarter of long-term ERT patients are inadequate responders, the target population for next-generation enzyme replacement.
Pompe disease is caused by acid alpha-glucosidase (GAA) deficiency, and the UK Pompe Consortium (an academic-clinical network spanning GSTT/King's, Manchester, Birmingham, Addenbrooke's, and Edinburgh) coordinates shared care, a national registry, and research across an estimated 200 UK patients (infantile-onset and late-onset combined). Unlike some Gulf markets, the NHS newborn-screening programme does not currently include Pompe disease, so infantile-onset cases (roughly 12–18 per year) are diagnosed symptomatically; late-onset disease (LOPD) is typically diagnosed 5–10 years after first symptom, frequently misread initially as a limb-girdle myopathy.
The UK LOPD diagnostic pathway runs from unexplained proximal myopathy and elevated creatine kinase through metabolic genetics referral to a dried-blood-spot GAA enzyme assay (available at GSTT, Manchester, and Birmingham) and confirmatory GAA gene sequencing, offered free through the NHS Genomic Medicine Service — a journey the UK Pompe Consortium estimates at 3–8 years from first symptom. Alglucosidase alfa has never been formally appraised by NICE; enzyme replacement therapy continuation is instead governed by NHS clinical commissioning policy, which requires forced vital capacity and six-minute-walk-test monitoring at baseline, 12, and 24 months, with continuation contingent on at least 10% improvement or stabilisation. Roughly 60% of patients on ERT for more than five years show continued stabilisation, but around 25% (an estimated 45–50 UK patients) show decline despite treatment and are the immediate target population for next-generation enzyme replacement: avalglucosidase alfa, already NICE-recommended as TA821 (2022).
UK Pompe disease ERT outcome monitoring under NHS clinical commissioning policy
| Segment | Estimated UK Patients | Monitoring Result | NHS Clinical Policy Status | Commercial Implication |
|---|---|---|---|---|
| Stabilised responders (>5 yrs ERT) | ~60% of treated cohort | FVC/6MWT stabilisation maintained | Continuation criteria met | Remain on alglucosidase alfa (Lumizyme/Myozyme) |
| Inadequate responders | ~25% (est. 45–50 patients) | FVC decline despite ERT | Continuation criteria marginal | Target population for avalglucosidase alfa (Nexviazyme, NICE TA821 recommended 2022) |
| Newly diagnosed LOPD | ~12–18 new IOPD cases/year; LOPD rate less defined | Baseline FVC/6MWT establishment | Pre-continuation-criteria | ERT initiation decision point |
Sources: NHS clinical commissioning policy (alglucosidase alfa continuation criteria); NICE TA821 (avalglucosidase alfa, 24 August 2022); UK Pompe Consortium registry 2023; UK Pompe Consortium outcomes registry 2023; UK Pompe Consortium diagnostic pathway guidelines 2022; NHS GMS GAA panel specifications.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- UK Pompe Consortium centre network
- infantile-onset vs late-onset case split
- the absence of Pompe from NHS newborn screening and its diagnostic consequence
Delivers
- NHS clinical-policy FVC/6MWT continuation criteria
- responder vs inadequate-responder split
- addressable patient count (45–50) for avalglucosidase alfa
- TA821 commercial-arrangement terms
Delivers
- Limb-girdle myopathy misdiagnosis pattern
- DBS GAA assay and gene-panel access points
- NHS GMS free testing
- referral pathway from primary presentation to Consortium centre
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- How acid alpha-glucosidase (GAA) deficiency drives both infantile-onset and late-onset Pompe disease phenotypes
- Why the disease's biology creates a diagnostic overlap with limb-girdle myopathy in late-onset presentation
- The UK Pompe Consortium's shared-care network across GSTT/King's, Manchester, Birmingham, Addenbrooke's, and Edinburgh
- Sizing the roughly 200-patient UK population, including 12-18 new infantile-onset cases a year alongside the late-onset cohort
- The referral pathway from unexplained proximal myopathy and elevated creatine kinase to dried-blood-spot GAA assay and confirmatory gene sequencing
- Why LOPD is frequently misread initially as limb-girdle myopathy, driving a 3-8 year diagnostic delay from first symptom
- Why alglucosidase alfa has never been formally appraised by NICE, leaving ERT continuation governed by NHS clinical commissioning policy
- The FVC and six-minute-walk-test monitoring schedule at baseline, 12, and 24 months that determines continuation
- Why roughly 60% of patients on ERT for over five years show continued stabilisation while about 25% show decline
- Sizing the 45-50 UK patients with inadequate ERT response, the immediate target population for next-generation enzyme replacement
- How avalglucosidase alfa's NICE recommendation (TA821, 2022) positions it against the inadequate-responder population
- What TA821's commercial-arrangement terms mean for next-generation ERT uptake among stabilised versus declining patients
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
UK Pompe disease landscape is built from primary NHS and NICE sources, including NHS clinical commissioning policy for ERT continuation criteria, NHS Genomic Medicine Service GAA gene panel specifications, and NICE TA821 for avalglucosidase alfa, together with UK Pompe Consortium registry and outcomes data, not secondary summaries or unverified estimates.
Key sources: NHS clinical commissioning policy (alglucosidase alfa continuation criteria); NICE TA821 (avalglucosidase alfa, 2022); UK Pompe Consortium registry 2023; UK Pompe Consortium diagnostic pathway guidelines 2022; UK Pompe Consortium outcomes registry 2023; NHS GMS GAA panel specifications.
- UK Pompe patient estimate verified against UK Pompe Consortium registry 2023
- LOPD diagnostic delay verified against UK Pompe Consortium diagnostic pathway guidelines 2022
- ERT continuation criteria and responder segmentation verified against NHS clinical commissioning policy and UK Pompe Consortium outcomes registry 2023
- GAA diagnostic testing access verified against NHS GMS GAA panel specifications
Frequently asked questions
Commission this assessment
AXLRx UK Pompe Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the UK Pompe disease patient population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.